Meropenem Hikma Farmacêutica (Portugal) (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, leading to weakened cell walls and bacterial cell death. Its high affinity for multiple PBPs gives it activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms.

The specific dose of Meropenem Hikma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data for meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Meropenem shares the carbapenem class’s broad spectrum and resistance to most beta‑lactamases, similar to imipenem or ertapenem. Compared with imipenem, meropenem has a lower risk of seizures and does not require co‑administration with cilastatin. Its dosing flexibility and stability make it a preferred option for many severe infections.

Meropenem Hikma should be stored below 25 °C in its original packaging, protected from moisture and light. Once reconstituted for intravenous administration, the solution should be used promptly or stored according to the manufacturer’s instructions, typically at refrigerated temperatures for a limited period.

Meropenem Hikma is supplied as a sterile powder for intravenous infusion. The powder is reconstituted with a suitable diluent and administered by slow IV infusion over 15–30 minutes, according to the prescribing clinician’s instructions and the patient’s clinical condition.

The most serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, and severe allergic reactions such as anaphylaxis. Clinicians should also monitor for Clostridioides difficile‑associated colitis and rare hematologic events like thrombocytopenia.

Meropenem should not be given to patients with a known hypersensitivity to meropenem, other carbapenems, or any beta‑lactam antibiotics. Caution is advised in patients with a history of seizures, severe renal impairment, or those receiving interacting medications that could increase toxicity.